Capital Project Engineering in Pharma Summit

Memo

The surge in demand for speed-to-market patient delivery of drugs is exponential, meaning that the pressure to develop new drug-development sites is now more prominent than ever before. Excitement in the field is evident: Novartis has invested in 3 new manufacturing sites, BMS is scaling up production for Breyanzi, and Thermo Fisher has opened a 300,000 ft² viral vector production site in Boston. The Capital Project Engineering in Pharma Summit will cover new-builds, brownfields and expansion projects - enabling Project Managers and Engineers to achieve operational readiness on these projects. Join us and learn how to incorporate an adaptable project design, mitigate risks from the get go, and handle equipment with optimal efficiency. This unique event is the only pharma-specific and end-user led meeting focused on bridging internal and external stakeholders to deliver new sites on time and on budget. URLs:Tickets: https://go.evvnt.com/1541878-2?pid=5569 Brochure: https://go.evvnt.com/1541878-3?pid=5569  Date and Time: On Tue, 23 May 2023 09:00 - Thu, 25 May 2023 15:45 Venue details: Wyndham Boston Beacon Hill, 5 Blossom Street, Boston, Massachusetts, 02114, United States Prices:Drug Developer - Conference + 2 Workshops: USD 3597.00,Drug Developer - Conference + 1 Workshop: USD 3098.00,Drug Developer - Conference Only: USD 2599.00,Solution Provider - Conference + 2 Workshops: USD 5297.00,Solution Provider - Conference + 1 Workshop: USD 4548.00,Solution Provider - Conference Only: USD 3799.00 Speakers: Alex Oliveira, Senior Engineering Manager, ILC Dover, Brenden Alexander, Director, Day 2 Construction and Global Facilities, SmartLabs, David Wood, Director - Capital Project Management, BioMarin Pharmaceutical, Demet Aybar, Director of Facilities, Lab Operations and EH and S, Strand Therapeutics, Ellie Nguyen, Project Manager/Program Manager, Thermo Fisher, Erika Whyte, Senior Director Facilities, ROME Therapeutics, Jacob Warburg, Guerbet, Jeffrey MacKay, VP, Facilities and Real Estate, Foundation Medicine, Jesper Naucler, Head of Capital Projects, Global Engineering, AstraZeneca, Krisha Panchalingam, Senior Manager, Lab Operations, Abata Therapeutics, Lora Cameron-Landis, Principal Engineer, Keros Therapeutics, Matthew Treon, Co-Founder, Vice President, Corporate Engineering and Capital Projects, Lykan Bioscience, Matthew VanGessel, Senior Manager, Capital Projects and Expansion, Grand River Aseptic, Michael Sproul, Senior Engineering Project/Portfolio Manager, Catalent Biologics, Rebecca Ford, Associate Director, Engineering, Major Capital and Project Management Office, Eli Lilly and Co., Renato Pedroso, Site Engineering Head ,Takeda, Robert Clark, Director - Corporate Project, Newlight Technologies Inc.